Ardia Announces Additional Positive Results On Gout Drug - Wall Street Journal

Ardia Announces Additional Positive Results On Gout Drug Wall Street Journal ... of uric acid levels when combined with currently marketed agents for the treatment of gout," said President and Chief Executive Barry D. Quart. ... Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate ...PR Newswire (press release) Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate ...MarketWatch (press release) all 17 news articles »

Novartis ACZ885 prevented acute flares in gout patiends shows study - Frontier India - News, Analysis, Opinion

Novartis ACZ885 prevented acute flares in gout patiends shows study Frontier India - News, Analysis, Opinion “Gout patients frequently experience painful flares with debilitating consequences on their quality of life because current treatment strategies are not ... EULAR: Novel Agent Eases Gout PainMedPage Today all 8 news articles »

Regeneron gout drug meets study goals - BusinessWeek

Regeneron gout drug meets study goals BusinessWeek A gout treatment candidate from Regeneron Pharmaceuticals met key goals in a late-stage clinical trial, the company said Wednesday. ... Regeneron gout drug works in one trial, fails otherReuters All About Gout: Arcalyst Meets Phase III Prophylaxis EndpointBioWorld Online Regeneron Sees Mixed Results on Gout Drug TrialsWall Street Journal Monthly Prescribing Reference -Daily Markets -Motley Fool all 74 news articles »

Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease - MarketWatch (press release)

Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease MarketWatch (press release) Without immediate treatment, major exacerbations of Behcet's uveitis may lead to retinal detachment, vitreous hemorrhage, glaucoma and eventual blindness. ... and more »